Edwards’ Aortic Valve With Resilia Tissue Shows Favorable Durability, Safety and Efficacy Outcomes in Seven Year Data

Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration in bioprosthetic aortic valves with the company’s innovative RESILIA tissue.